Search results for "10031 Clinic for Angiology"

showing 10 items of 32 documents

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ER…

2020

Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in proposing the best management strategies for an individual patient with a given condition. Guidelines and their recommendations should facilitate decision making of health professionals in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health professional(s) in consultation with the patient and caregiver as appropriate.

ORAL ANTICOAGULANT-THERAPYdiagnosis[SDV]Life Sciences [q-bio]Medizin030204 cardiovascular system & hematologyEmbolectomyGuidelineRECURRENT VENOUS THROMBOEMBOLISM0302 clinical medicinePregnancyDaily practiceDiagnosisPulmonary medicineVenous thrombosisPulmonary MedicineThrombolytic TherapyDEEP-VEIN THROMBOSISDisease management (health)Societies MedicalComputingMilieux_MISCELLANEOUShealth care economics and organizationsRisk assessmentddc:616RIGHT-VENTRICULAR DYSFUNCTIONDisease ManagementShockMOLECULAR-WEIGHT HEPARINThrombolysishumanities3. Good healthPulmonary embolismEuropeAnticoagulation; Biomarkers; Diagnosis; Dyspnoea; Echocardiography; Embolectomy; Guidelines; Heart failure; Pregnancy; Pulmonary embolism; Right ventricle; Risk assessment; Shock; Thrombolysis; Treatment; Venous thromboembolism; Venous thrombosismedicine.veinEchocardiographyAcute DiseaseRight ventricleMedical emergencyCardiology and Cardiovascular MedicineRisk assessmentguidelines; pulmonary embolism; venous thrombosis; shock dyspnoea; heart failure: right ventricle: diagnosis; risk assessment: echocardiography; biomarkers; treatment; anticoagulation; thrombolysis; pregnancy; venous thromboembolism; embolectomyDiagnosiVenous thromboembolismthrombolysiseducationCardiologyMEDLINEThrombolysiHeart failure610 Medicine & healthGuidelinesInferior vena cava2705 Cardiology and Cardiovascular MedicineEXTRACORPOREAL MEMBRANE-OXYGENATION03 medical and health sciencesAnticoagulationMedicalDyspnoeamedicineHumansRIGHT HEART THROMBIVENTILATION-PERFUSION SCINTIGRAPHYshock dyspnoeaHealth professionalsbusiness.industryINFERIOR VENA-CAVA10031 Clinic for Angiologyheart failure: right ventricle: diagnosisPulmonary embolismAnticoagulantsbiomarkersrisk assessment: echocardiography030229 sport sciencesBiomarkermedicine.diseaseTreatmentINHALED NITRIC-OXIDESocietiesbusinessBiomarkers
researchProduct

Thromboprophylaxis after renal transplantation and patient risk stratification: The case of mTOR inhibitors.

2020

Oncologymedicine.medical_specialtymTORiPatient risk2720 HematologyMEDLINE610 Medicine & healthStratification (mathematics)Internal medicinemedicineHumansEverolimusSirolimusEverolimusHematologybusiness.industry10031 Clinic for AngiologyTOR Serine-Threonine KinasesAnticoagulantsHematologyVenous ThromboembolismDiscovery and development of mTOR inhibitorsKidney TransplantationTransplantationRenal transplantSirolimusbusinessImmunosuppressive AgentsVenous thromboembolismmedicine.drugThrombosis research
researchProduct

Comment on “Worldwide Distribution of PK Deficiency: the Defect Seems Mainly Concentrated in West African Countries and the United States.”

2021

PKlcsh:RC633-647.5business.industry10031 Clinic for Angiology2720 HematologyPK DEFICIENCYDistribution (economics)610 Medicine & healthPK deficiency2725 Infectious Diseaseslcsh:Diseases of the blood and blood-forming organsHematologyUnited StatesWest African CountriesWest africanInfectious Diseases10032 Clinic for Oncology and HematologyDeficiencyMedicinebusinessSocioeconomicsLetter to the EditorMediterranean Journal of Hematology and Infectious Diseases
researchProduct

The Post-COVID-19 Functional Status scale: a tool to measure functional status over time after COVID-19

2020

Since the outbreak of the Coronavirus disease 2019 (COVID-19) pandemic, most attention has focused on containing transmission of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and addressing the surge of critically ill patients in acute care settings. Indeed, as of April 29th 2020, over 3 million confirmed cases have been accounted for globally [1]. In the coming weeks and months, emphasis will gradually involve also post-acute care of COVID-19 survivors. It is anticipated that COVID-19 may have a major impact on physical, cognitive, mental and social health status, also in patients with mild disease presentation [2]. Previous outbreaks of coronaviruses have been associate…

Pulmonary and Respiratory Medicine2019-20 coronavirus outbreakActivities of daily livingCoronavirus disease 2019 (COVID-19)Scale (ratio)IMPACTPneumonia ViralMeasure (physics)610 Medicine & healthMachine learningcomputer.software_genreDiagnostic Self EvaluationBetacoronavirusDiagnostic Self Evaluation03 medical and health sciences0302 clinical medicineSurveys and QuestionnairesActivities of Daily LivingCorrespondenceHumansMedicinePatient Reported Outcome Measures030212 general & internal medicinePandemicsCOVIDSARS-CoV-2business.industry10031 Clinic for AngiologyCOVID-19Recovery of FunctionPhysical Functional Performance030228 respiratory system2740 Pulmonary and Respiratory MedicineQuality of LifeFunctional statusArtificial intelligenceCoronavirus InfectionsbusinesscomputerCoronavirus Infections
researchProduct

A model for estimating the health economic impact of earlier diagnosis of chronic thromboembolic pulmonary hypertension

2021

Background Diagnostic delay of chronic thromboembolic pulmonary hypertension (CTEPH) exceeds 1 year, contributing to higher mortality. Health economic consequences of late CTEPH diagnosis are unknown. We aimed to develop a model for quantifying the impact of diagnosing CTEPH earlier on survival, quality-adjusted life-years (QALYs) and healthcare costs. Material and methods A Markov model was developed to estimate lifelong outcomes, depending on the degree of delay. Data on survival and quality of life were obtained from published literature. Hospital costs were assessed from patient records (n=498) at the Amsterdam UMC – VUmc, which is a Dutch CTEPH referral center. Medication costs were ba…

Pulmonary and Respiratory Medicine7medicine.medical_specialtyRespiratory SystemImproved survival610 Medicine & healthQuality of lifeQUALITY-OF-LIFEOriginal Research ArticlesHealth caremedicineEconomic impact analysisIntensive care medicineANGIOPLASTYEconomic consequencesDisease burdenPulmonary Vascular DiseaseScience & Technologybusiness.industry10031 Clinic for AngiologyR2740 Pulmonary and Respiratory MedicineReferral centerMedicineChronic thromboembolic pulmonary hypertensionbusinessLife Sciences & Biomedicine
researchProduct

Management of acute pulmonary embolism: towards a (truly) global reach

2021

The study by Z. Zhai and colleagues provides an overview of the developments observed as risk-adapted management strategies for acute pulmonary embolism have been progressively introduced and optimised in the Chinese healthcare systemhttps://bit.ly/3swGht2

Pulmonary and Respiratory Medicinemedicine.medical_specialtybusiness.industry10031 Clinic for AngiologyMEDLINE610 Medicine & healthmedicine.diseasePulmonary embolism2740 Pulmonary and Respiratory MedicineHealth careAcute DiseaseMedicineHumansbusinessIntensive care medicinePulmonary Embolism
researchProduct

Antithrombotics and new interventions for venous thromboembolism: Exploring possibilities beyond factor IIa and factor Xa inhibition.

2021

Abstract Direct oral anti–activated factor X and antithrombin agents have largely replaced vitamin K antagonists as the standard of care in treatment of venous thromboembolism. However, gaps in efficacy and safety persist, notably in end‐stage renal disease, implantable heart valves or assist devices, extracorporeal support of the circulation, and antiphospholipid syndrome. Inhibition of coagulation factor XI (FXI) emerges as a promising new therapeutic target. Antisense oligonucleotides offer potential advantages as a prophylactic or therapeutic modality, with one dose‐finding trial in orthopedic surgery already published. In addition, monoclonal antibodies blocking activation and/or activ…

medicine.drug_class2720 Hematologyvenous thromboembolism610 Medicine & healthBioinformaticslaw.inventionchemistry.chemical_compoundRandomized controlled trialAntiphospholipid syndromelawAntithromboticMedicineDiseases of the blood and blood-forming organsFactor XIIbusiness.industrycatheter(s)Factor X10031 Clinic for AngiologyAntithrombinAnticoagulantanticoagulantHematologycontact systemmedicine.diseasefactor XIPulmonary embolismchemistryRC633-647.5businessState of the Art Isth 2020medicine.drugResearch and practice in thrombosis and haemostasis
researchProduct

COVID-19 in thrombosis research: An editorial perspective

2021

medicine.medical_specialty2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)SARS-CoV-2business.industrySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)10031 Clinic for AngiologyPerspective (graphical)2720 HematologyMEDLINECOVID-19Thrombosis610 Medicine & healthHematologyThrombosis ResearchEditorialHumansMedicinebusinessIntensive care medicine
researchProduct

Severe plasma prekallikrein deficiency : clinical characteristics, novel KLKB1 mutations, and estimated prevalence

2020

BACKGROUND Severe plasma prekallikrein (PK) deficiency is an autosomal-recessive defect characterized by isolated activated partial thromboplastin time prolongation. To date, no comprehensive methodologically firm analysis has investigated the diagnostic, clinical, and genetic characteristics of PK deficiency, and its prevalence remains unknown. PATIENTS/METHODS We described new families with PK deficiency, retrieved clinical and laboratory information of cases systematically searched in the (gray) literature, and collected blood of these cases for complementary analyses. The Genome Aggregation Database (gnomAD) and the population-based Gutenberg Health Study served to study the prevalence …

medicine.medical_specialty2720 HematologyPopulation610 Medizin610 Medicine & healthReference range030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinePlasma PrekallikreinInternal medicine610 Medical sciencesPrevalenceHumansMedicineeducation610 Medicine & healthFactor XIIeducation.field_of_studymedicine.diagnostic_testbusiness.industry10031 Clinic for AngiologyPrekallikreinPrekallikreinHematologyBlood Coagulation Disordersmedicine.diseaseThrombosisMutation10032 Clinic for Oncology and HematologyCohortbusinessPartial thromboplastin time
researchProduct

Lemierre syndrome: Current evidence and rationale of the Bacteria-Associated Thrombosis, Thrombophlebitis and LEmierre syndrome (BATTLE) registry.

2020

Abstract Lemierre syndrome is a rare but potentially fatal condition characterized by septic thrombophlebitis of the head and neck district, preferentially affecting adolescents and young adults and manifesting as a complication of a local bacterial infection – typically, a pharyngotonsillitis or an abscess. It is historically associated with the Gram-negative anaerobic rod Fusobacterium necrophorum and with thrombophlebitis of the internal jugular vein. However, its definition has never been firmly established, and its spectrum within the continuum of bacteria-associated thrombophlebitis may be larger than what presumed so far. Recent evidence suggests that its prognosis remains serious ev…

medicine.medical_specialtyAdolescent2720 Hematologyved/biology.organism_classification_rank.species610 Medicine & health030204 cardiovascular system & hematologyThrombophlebitis03 medical and health sciencesYoung Adult0302 clinical medicineDisease registryFusobacterium necrophorumEpidemiologymedicineHumansSeptic thrombophlebitisRegistriesAbscessIntensive care medicinebiologyved/biologybusiness.industry10031 Clinic for AngiologyHematologyLemierre SyndromeThrombophlebitisbiology.organism_classificationmedicine.diseasePharyngitisAnti-Bacterial AgentsFusobacterium necrophorumFusobacterium030220 oncology & carcinogenesismedicine.symptomJugular VeinsbusinessThrombosis research
researchProduct